Breast cancer drug Palbociclib freezes the growth of aggressive tumours This delays the need for chemotherapy, enabling women to lead normal lives Rationing watchdog NICE rejecting the drug due to its £2,950 a month cost Drug will only be viewed as cost-effective if its price can be cut to £590 a month A revolutionary drug considered...